Alcohol and Drug Abuse Research Center
Center for Depression, Anxiety and Stress Research
McLean Imaging Center
Clinical Unit Based Research
Mailman Research Center
Shervert H. Frazier Research Institute
Clinical Trials
Inventions for License
Research News


MCL 1778.0: Dopamine D4 Receptor-Selective Antagonists as Treatment for Attention Deficit-Hyperactivity Disorder

Ross Baldessarini, M.D., et al.

Background and Description

The invention is based on the finding that motor hyperactivity can be dose-dependently reversed by receptor-specific antagonists of a key neuronal receptor. The invention therefore comprises compounds for treating motor hyperactivity disorders such as attention deficit-hyperactivity disorder (ADHD), and methods of using such compounds in treatment of these diseases.

Potential Commercial Uses

The compounds and methods of the invention will be useful in treating ADHD and related disorders. These compounds are expected to be superior to conventional therapies using psychostimulants in that they do not stimulate dopamine release or block its inactivation by reuptake or transport.

Publication and Patent Status

McLean Hospital is the owner of issued U.S. patent number 6,747,029 claiming this invention. (USPTO # 6,747,029)

Licenses Available

McLean Hospital is offering a worldwide exclusive license to this technology.

For more information, please contact:

David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax